4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
Health-economic analyses of SURMOUNT-3: cost per QALY for tirzepatide after intensive lifestyle intervention, payer-coverage barriers, list-price vs net-price gaps, and value considerations for patients and clinicians.
Analysis of SURMOUNT-3 long-term follow-up, weight regain patterns after tirzepatide discontinuation, durability of cardiometabolic benefits, and what the trial's design tells us about sustained obesity treatment.
Detailed breakdown of the SURMOUNT-3 trial results for tirzepatide after intensive lifestyle intervention, including effect sizes, confidence intervals, secondary endpoints, and response distribution.
SURMOUNT-3: adults who lost 5%+ weight via 12-week lifestyle program lost 21.1% more with tirzepatide vs 3.3% with placebo over 72 weeks.